Dissemination (Spotlight)

Tardive dyskinesia impacts both the patients living with the movement disorder and those who care for them.

Patients consistently felt possible TD impacted their lives, regardless of rating method, suggesting clinician assessments might miss its actual burden.

Researchers proposed a hypothesis linking dysfunctions in the striatum and the dorsal diencephalic connection system (DDCS) to classic tardive dyskinesia (TD).

Healthcare professionals should consider a complete therapeutic approach that includes the input of caregivers assisting patents with TD.

Resting-state functional MRI results show that patients with schizophrenia and tardive dyskinesia have altered cerebral regional homogeneity.

Physicians typically address movement disorders, such as tardive dyskinesia, during in-person examinations; however, a recent study shows that telehealth visits can be a part of treatment plans.

Patients with tardive dyskinesia being treated with vesicular monoamine transporter 2 inhibitors may see improvement in well-being along with TD symptoms.

Between 20% and 30% of patients with schizophrenia (SCZ)—and up to 50% patients with SCZ older than 50—develop tardive dyskinesia (TD), according to a study published in Genes & Genomics.

An uptick in biomarker testing for non-small cell lung cancer (NSCLC) over the past decade indicates an ongoing trend toward personalization of treatment choices.

First-line treatment that aligns with the results of biomarker testing and treatment guidelines is linked with better survival outcomes in patients with advanced or metastatic NSCLC.

Biomarker testing in non-small cell lung cancer informs therapeutic decisions at all stages of...

Comprehensive biomarker testing of patients with non-small lung cancer (NSCLC) is a critical part...